𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A double-blind randomized controlled trial of colchicine in patients with hepatitis B virus-related postnecrotic cirrhosis

✍ Scribed by Yuan-Jen Wang; Shou-Dong Lee; Mao-Chih Hsieh; Han-Chieh Lin; Fa-Yauh Lee; Shyh-Haw Tsay; Yang-Te Tsai; Oliver Yoa-Pu Hu; Ming-Lu King; Kwang-Juei Lo

Book ID
118567230
Publisher
Elsevier Science
Year
1994
Tongue
English
Weight
472 KB
Volume
21
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Treatment of hepatitis C virus–related c
Treatment of hepatitis C virus–related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment
✍ Dominique-Charles Valla; Michele Chevallier; Patrick Marcellin; Jean-Louis Payen πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 97 KB πŸ‘ 1 views

To examine the effects of interferon (IFN) therapy on clinical, biochemical, and histological features in patients with compensated hepatitis C virus (HCV)-related cirrhosis, we have conducted a randomized, controlled trial of IFN therapy versus observation. Eight centers included a total of 99 pati

Phase 1B, randomized, double-blind, dose
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus
✍ John G. McHutchison; Bruce R. Bacon; Stuart C. Gordon; Eric Lawitz; Mitchell Shi πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 397 KB πŸ‘ 1 views

CPG 10101, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV. In this multicenter Phase 1b trial, 60 HCV-positive patients (50 genotype 1 HCV) were randomized and